Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise Jan. 6, 2004 By Karen Carey The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)Read More
ILEX Starts Clofarabine Filing Process, Begins Rolling NDA Oct. 23, 2003 By Karen Carey In a move to launch its second product in the U.S., ILEX Oncology Inc. filed the first part of a rolling new drug application on Wednesday for Clofarabine to treat refractory or relapsed acute leukemia in children.(BioWorld Today)Read More
